Brussels, BELGIUM – November 6, 2025 – The Oncidium foundation, an independent non-profit organization dedicated to ensuring equal access to radioligand therapy for cancer care, today announces its recognition by the U.S. Internal Revenue Service of its newly formed Oncidium Foundation USA as a 501(c)(3) tax-exempt public charity.
This milestone marks a pivotal step in advancing the foundation’s global mission to make life-saving nuclear medicine and theranostic solutions accessible to patients everywhere. The 501(c)(3) designation enables Oncidium Foundation USA to expand partnerships, accept tax-deductible donations, and directly engage with the American medical, research, and patient communities—accelerating efforts to turn scientific innovation into tangible patient benefit to all.
The USA branch is serving as a strategic bridge between American innovation and global patient access, fostering collaboration among clinicians, industry leaders, and advocacy groups to break down barriers to Radioligand Therapy in cancer care.
“Our vision is to bring hope and actionable options to every patient who stands at the intersection of the fight against cancer and nuclear medicine,” said Jean-Luc Vanderheyden, Ph.D., Head of Oncidium foundation USA. “With our formal U.S. launch and tax-exempt status secured, we are positioned as a trustworthy organization to build bridges across disciplines and geographies so that the promise of molecular imaging and theranostics moves from promise to practice.”
“The launch of Oncidium Foundation USA marks a pivotal moment of convergence among patients, clinicians, industry, and policymakers,” added Rebecca Lo Bue, CEO of the Oncidium foundation. “We invite like-minded organizations to join us in bringing education, awareness, and access to patients who often face barriers to emerging diagnostics and therapies. Together, we can ensure that advanced molecular medicine is not just an aspiration, but a reality.”
As next steps, Oncidium Foundation USA will launch a national awareness and education campaign uniting physicians, researchers, and patient advocates through high-impact events and collaborations. Planned engagements include participation and patient advocacy initiatives at major conferences such as SNMMI, ASCO, AUA, and ASTRO.
Currently, U.S. patients can already benefit from the foundation’s Oncidium Global Treatment Center Finder, a public database designed to help patients locate validated theranostic and nuclear-medicine centers and access accurate, up-to-date information about available treatment options.
Through its growing U.S. presence, Oncidium Foundation aims to empower patients, support innovation, and reduce inequities in access to advanced cancer care, ensuring that promising radioligand therapies reach those who need them most.
***
About Oncidium foundation USA
Oncidium Foundation USA is a U.S.-based 501(c)(3) nonprofit organization dedicated to expanding equitable access to radioligand therapy (RLT) for cancer care. Its mission includes educating patients, supporting collaboration among clinicians, researchers, and industry, and advancing awareness and adoption of radiotheranostics across the United States.
Founded under the global umbrella of the Oncidium Foundation, an independent nonprofit organization working worldwide to improve access to radioligand therapy, Oncidium Foundation USA contributes to the shared goal of accelerating patient access to advanced molecular medicine.
